Ruthenium−Ferrocene Bimetallic Agent
- Scientists from Agharkar Research Institute (ARI), Pune, have discovered a Ruthenium−Ferrocene bimetallic agent that shows a highly potent antitumor effect in platinum-resistant cancers.
- Platinum drugs are the frontline treatment option for many cancers. But their broad applicability is severely limited due to the fast development of resistance against these drugs.
- The new agent is the first rationally designed Ruthenium-Ferrocene bimetallic complex identified to date that possesses low toxicity but both potent antitumor as well as anti-angiogenic properties.
- The complex can inhibit primary tumor growth and metastasis as well as kill cancer cells ....
Do You Want to Read More?
Subscribe Now
To get access to detailed content
Already a Member? Login here
